News - Dr. Marty Makary Resigns as FDA Commissioner

In a surprise move on Tuesday, Dr. Marty Makary resigned from his position as U.S. Food and Drug Administration (FDA) Commissioner after a tenure highlighted by significant policy reforms but also marked by clashes with various groups, including the White House, industry stakeholders, and anti-abortion activists. Dr. Makary's departure comes after 13 months in office, during which he pushed for major FDA reforms, placing emphasis on expeditious drug reviews and progressive changes in food policy. President Donald Trump addressed the resignation, acknowledging Dr. Makary's achievements and contributions to the FDA. Trump announced that Kyle Diamantas, previously the Deputy Commissioner for Food, would take on the role of acting commissioner while the administration searches for a permanent replacement. President Trump conveyed his appreciation for Makary's leadership through various channels, including posting on Truth Social. Dr. Makary's legacy includes introducing 50 significant FDA reforms, as per his resignation text message shared by Trump. He also made headlines for his outspoken views during the COVID-19 pandemic, gaining popularity among conservatives for his criticism of federal mandates and pandemic policies. However, his decisions often drew criticism and sparked disputes, particularly regarding controversial drug approvals and food safety standards. Makary's background as a Johns Hopkins surgeon and healthcare commentator provided him with a platform to influence policy that he used effectively to further planned reforms during his term. However, despite his successes, disagreements with political figures and industry executives overshadowed some of his accomplishments. The FDA now faces a leadership gap with Makary's resignation adding to the instability in federal health agencies, compounded by a lack of permanent leadership at the Centers for Disease Control and Prevention (CDC). Diamantas takes over as Acting Commissioner, poised to navigate the challenges of maintaining the reform momentum and addressing the unfinished business left in Makary's wake. FDA's internal dynamics have been subject to scrutiny under Makary's leadership, experiencing staff turnover and facing accusations of political interference. As Deputy Commissioner for Food, Diamantas was involved in spearheading recent changes in policy related to food dye, signaling that he might pursue continuity in regulatory reform during his interim leadership. As the FDA transitions under new temporary leadership, stakeholders are keenly observing whether the organization will continue its trajectory of aggressive reform or recalibrate under new guidance.